Roberts Brandi sold $136K of DFTX

Roberts Brandi (Chief Financial Officer) sold 3,013 shares of Definium Therapeutics, Inc. (DFTX) at $45.03 ($0.14M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Roberts Brandi
Published Jun 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
high confidence
Mentioned
$DFTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

This disclosure updates the record of insider activity but does not introduce new company fundamentals (no guidance, trial, deal, or regulatory action).

02

Market read

Traders may monitor for patterns in insider selling, but this specific transaction is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The article lacks context on total insider holdings, prior sale cadence, and whether other insiders/large holders acted—so the signal may be overstated.

Relevance 3/10Novelty 3/10Timing: after-hours/filing day (2026-06-26) insider transaction disclosure

Background

The article is an SEC Form 4 insider transaction report for Definium Therapeutics, Inc.

Company-level read

Ticker impact

$DFTXNeutralHigh confidence
Context

SEC Form 4 shows CFO Roberts Brandi sold 3,013 shares of Definium Therapeutics at $45.03 on 2026-06-25 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by the CFO; the article provides no new operational, financial, or regulatory developments.

Market effects

Minimal; single-company insider sale with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Definium Therapeutics, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Roberts Brandi

    Chief Financial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT